6996 — Antengene Share News
0.000.00%
Last trade - 00:00- HK$1.93bn
- HK$1.39bn
- CNY105.34m
Brief: Antengene Corp Expects HY Profit Of RMB195 MLN-RMB238 MLN
Brief: Antengene Corp Receives Initial $60 Million Upfront Payment From UCB
Brief: Antengene Corp Intends To Repurchase Up To 67.92 Million Shares
Brief: Antengene Corp Enters Exclusive License Agreement With K2 Therapeutics For Atg-106
Brief: Antengene Says China NMPA Approves IND Application For Phase I Study Of ATG-201
Brief: Antengene Receives CDE Endorsement For Phase III Clinch-3 Study Of ATG-22 In China
Brief: Antengene Corp Says CEO Purchases 200,000 Shares Of Co
Belgium's UCB in autoimmune drug deal with Antengene
Brief: Antengene And UCB Enter Global License Agreement For ATG-201, A CD19/CD3 Bispecific T-Cell Engager For Autoimmune Diseases
Brief: Antengene Says Malaysian National Pharmaceutical Regulatory Agency Approves Xpovio For Relapsed Or Refractory DLBCL
Brief: Antengene Corp Says Xpovio Approved In Hong Kong For Two Additional Indications
Brief: Antengene Corp Says China's NMPA Approves IND Application For ATG-022 Study
Brief: Antengene Announces IND Approval In China For Phase Ib/II Study Of ATG-022 In Combination With Keytruda
Brief: Antengene Corp To Repurchase Shares At Maximum Price Of Hk$40 Mln
Brief: Antengene Says ATG-022 Granted Breakthrough Therapy Designation For Gastric Cancer By Center For Drug Evaluation Of China NMPA
HK-listed Antengene at 2-1/2-year peak on Xpovio approval in China
Brief: Antengene Corp Says Xpovio Approved In China For Second-Line Multiple Myeloma Treatment
Brief: Antengene Announces Intention To Conduct On-Market Share Repurchase
Brief: Antengene Gets Approval Of NDA By Indonesia National Agency Of Drug And Food Control For Xpovio